Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) released its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06), FiscalAI reports. Senseonics Holdings, Inc. Common Stock had a negative net margin of 195.72% and a negative return on equity of 102.69%. The firm had revenue of $11.71 million during the quarter.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

• Q1 commercial momentum: Net revenue was $11.7 million with a 58% gross margin, and management raised 2026 guidance to $60M–$64M, signaling early validation of the in‑house commercial model.
• U.S. commercial integration and channels: The Ascensia U.S. transition was described as seamless, direct‑to‑consumer new patient shipments accounted for ~60% of additions and nearly doubled YoY, and EonCare now performs over one‑third of insertions, supporting the company’s goal to double U.S. patients in 2026.
• Product pipeline progress: Senseonics is on track for Gemini in H1 2027 and plans a first‑in‑human trial for Freedom in H2 2026, while advancing app enhancements and manufacturing scale‑up.
• Financing strengthens runway: The company raised $92 million in equity and expanded its Hercules credit facility to $140 million (with an additional $20M drawn), providing capital to fund commercialization and next‑gen launches.
• Higher costs and cash burn: SG&A and operating expenses rose sharply (Q1 SG&A of $30.2M), net loss widened to $32.3M, and 2026 guidance implies $150M–$160M operating expenses and $110M–$120M cash utilization, indicating continued near‑term losses despite new financing.

Senseonics Holdings, Inc. Common Stock Price Performance

SENS stock traded down $0.33 during trading on Friday, reaching $5.03. 4,738,048 shares of the stock traded hands, compared to its average volume of 616,645. The firm’s 50 day simple moving average is $6.64. Senseonics Holdings, Inc. Common Stock has a 52-week low of $4.79 and a 52-week high of $14.50. The company has a quick ratio of 4.55, a current ratio of 4.83 and a debt-to-equity ratio of 0.58. The firm has a market cap of $210.23 million, a price-to-earnings ratio of -2.98 and a beta of 1.05.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Stifel Nicolaus set a $9.00 price target on Senseonics Holdings, Inc. Common Stock in a research report on Tuesday, March 3rd. Weiss Ratings assumed coverage on Senseonics Holdings, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “sell (d-)” rating for the company. Finally, TD Cowen reissued a “buy” rating on shares of Senseonics Holdings, Inc. Common Stock in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.38.

Insider Transactions at Senseonics Holdings, Inc. Common Stock

In other news, CEO Timothy T. Goodnow purchased 17,225 shares of the stock in a transaction on Friday, March 13th. The stock was purchased at an average price of $5.79 per share, with a total value of $99,732.75. Following the completion of the transaction, the chief executive officer owned 651,243 shares in the company, valued at approximately $3,770,696.97. The trade was a 2.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Douglas A. Roeder purchased 17,500 shares of the stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $5.73 per share, with a total value of $100,275.00. Following the transaction, the director owned 119,731 shares of the company’s stock, valued at $686,058.63. This trade represents a 17.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 4.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SENS. Ausdal Financial Partners Inc. lifted its stake in shares of Senseonics Holdings, Inc. Common Stock by 50.0% during the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares in the last quarter. Townsend Asset Management Corp NC ADV acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter worth about $60,000. GSK plc acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter worth about $60,000. Kestra Advisory Services LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the first quarter worth about $68,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter worth about $71,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.